Big Changes, Bigger Future - Associate Director, Marketing bei Merck: Mitarbeiterbewertung

4,0
6. Juli 2021
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

The company is a great. There are a lot of talented people here, and a lot of resources to get things done. The company has no deficit for providing employees with all the tools necessary to be impactful and to make real change. That can’t be said of every company. There’s also a decent desire to make everyone feel welcome, safe and heard, and to provide a quality work-life balance.

Kontras

Just like everyone company, where politics of people are key, Merck is no stranger. There’s a lot of layers and stakeholders. Which makes for a conservative and risk-averse environment. That doesn’t mean that risk is intolerable — you just better have everything figured out before you move everything along with you. Poor ideas and poorly substantive work will be crushed before novel ideas ever take off. That said, the right ears will give novel ideals some serious wings. Currently, Merck is feeling out it’s positions in a lot of high value areas due to the changes experienced by the industry post-COVID. It’s both an exciting time to be in such a company, but the hope is Merck’s layered governance doesn’t get in its own way.

Mehr Bewertungen zu Merck entdecken

5,0
30. Juni 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Excellent company to work with.

Kontras

No cons encountered so far

4,0
30. Juni 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Great benefits like medical/dentist/vision, pension, stock option, 401k match. Co workers are excellent, pretty good on site symposiums, lot of diversity clubs/activities. Innovation is extremely welcomed. Diversity in research portfolio. AI/ML is heavily invested to make databases more efficient.

Kontras

Micro managing, especially within the biologics department, potentially others. Promotions are limited, and pay bump is poor. Company invests too much in buying companies rather than keeping talent - lay offs let go of great talented people. Merck is afraid of investing into exploratory biology and doesn’t take risk - they even admit they would rather see other companies clinical data or R&D data rather than taking a risk. Although it’s slow going in building new software, current databases are slow and needs much improvement. Extremely poor work/life balance.

Bewertungen anzeigen nach: Hilfreich|Sterne|Datum|Alle